Shots:

• The Health Canada approval is based on four P-III studies ultIMMa-1- ultIMMa-2- IMMvent and IMMhance assessing Skyrizi (risankizumab) vs PBO- adalimumab- ustekinumab in >2000 adult patients with moderate to severe plaque psoriasis
• The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%- 84% & 75%); Skyrizi vs adalimumab- PASI 90 (72% vs 47%); Skyrizi vs ustekinumab- DLQI score (66% & 67% vs 43% & 47%); Skyrizi vs PBO- @28wks. sPGA 0/1 (87.4% vs 61.3%); improvement in  skin clearance with 3mos.dose regimen
• Skyrizi (risankizumab) is a humanized immunoglobulin mAb inhibits IL-23 by binding to its p19 subunit. On Mar’16- Boehringer Ingelheim & AbbVie collaborated to develop & commercialize Skyrizi globally

Ref: PRnewswire | Image: AbbVie